Account
Inquiry
XCE Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes research. This compound demonstrates superior efficacy in glucose control and weight management compared to selective GLP-1 receptor agonists.
The mechanism of action involves mimicking natural GIP at the GIP receptor while simultaneously activating GLP-1 receptors. This dual activity results in enhanced pancreatic β-cell responses, reduced glucagon secretion from α-cells, decreased hepatic glucose output, and appetite suppression through central nervous system effects.
Our XCE Tirzepatide is supplied as a white lyophilized powder with purity exceeding 98% by HPLC analysis. The product is carefully packaged to maintain stability and shipped under controlled conditions to ensure research integrity.
For laboratory use only. Not intended for human consumption. Researchers should handle this material according to institutional biosafety guidelines and applicable regulations.
